Company profile

J. J. Finkelstein
Incorporated in
Fiscal year end
Former names
Alpha 1 Biomedicals Inc, Alpha 1 Biomedicals Inc
IRS number

RGN stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


14 Nov 19
25 Jan 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 19.19K 19.19K 19.19K 19.19K
Net income -333.91K -388.45K -332.45K -263.83K
Diluted EPS 0 0 0 -0.01
Net profit margin -1740% -2024% -1732% -1375%
Operating income -286.5K -351.95K -322.86K -259.82K
Net change in cash -288.89K 508.14K 425.31K -158.78K
Cash on hand 881.82K 1.17M 662.57K 237.26K
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 69.67K 56.65K 93.31K 60.61K
Net income -1.99M 286.49K 229.13K -5.27M
Diluted EPS -0.02 0 0 -0.05
Net profit margin -2862% 506% 246% -8695%
Operating income -1.32M -1.44M -1.67M -1.71M
Net change in cash 55.55K -587.79K 451.87K -526.42K
Cash on hand 237.26K 181.71K 769.5K 317.63K

Financial data from company earnings reports

0.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1 2 -50.0%
Opened positions 1 0 +Infinity%
Closed positions 2 1 +100.0%
Increased positions 0 0 NaN%
Reduced positions 0 1 -100.0%
13F shares
Current Prev Q Change
Total value 22K 27K -18.5%
Total shares 140K 150K -6.7%
Total puts 0 0 NaN%
Total calls 0 0 NaN%
Total put/call ratio NaN NaN NaN%
Largest owners
Shares Value Change
Williams Jones Wealth Management 140K $22K NEW
Largest transactions
Shares Bought/sold Change
Williams Jones Wealth Management 140K +140K NEW
Williams Jones & Associates 0 -140K EXIT
Colony 0 -10K EXIT

Financial report summary

Management Discussion
  • ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • This Quarterly Report on Form 10-Q, including this Part I., Item 2., “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words “project,” “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “should,” “would,” “could,” “will,” “may” or other similar expressions. In addition, any statements that refer to projections of our future financial performance, our clinical development programs and schedules, our future capital resources and funding requirements, our expectations regarding future licenses of our technology, our anticipated growth and trends in our business and other characterizations of future events or circumstances are forward-looking statements. We cannot guarantee that we will achieve the plans, intentions or expectations expressed or implied in our forward-looking statements.  There are a number of important factors that could cause actual results, levels of activity, performance or events to differ materially from those expressed or implied in the forward-looking statements we make, including those described under “Risk Factors” set forth below in Part II., Item 1A. In addition, any forward-looking statements we make in this document speak only as of the date of this report, and we do not intend to update any such forward-looking statements to reflect events or circumstances that occur after that date.
  • We are a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. We have formulated Tß4 into three distinct product candidates in clinical development:
Content analysis ?
H.S. sophomore Avg
New words: hoped, IRB, Overview, partial, subsidiary, summer
Removed: accompany, authorized, behalf, certification, column, duly, eXtensible, formatted, furnished, hereof, heretofore, herewith, qualitative, quantitative, reference, referred, registrant, thereunto, undersigned, XBRL